SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines

References

• Callaway E. Are COVID surges becoming more predictable? New Omicron variants offer a hint. Nature. 2022;605(7909):204–11. doi:10.1038/d41586-022-01240-x.
   PubMed Web of Science ®Google Scholar
• Candido KL, Eich CR, de Fariña LO, Kadowaki, MK, da Conceição Silva, JL, Maller, A, Simão, RD. Spike protein of SARS-CoV-2 variants: a brief review and practical implications. Braz J Microbiol. 2022;53(3):1133–57. doi:10.1007/s42770-022-00743-z.
   PubMed Web of Science ®Google Scholar
• Murano K, Guo Y, Siomi H. The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines. Biochem Soc Trans. 2021;49(6):2879–90. doi:10.1042/BST20210859.
   PubMed Web of Science ®Google Scholar
• Noor R, Shareen S, Billah M. COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants. Bull Natl Res Cent. 2022;46:96. doi:10.1186/s42269-022-00787-z.
   PubMedGoogle Scholar
• Florentino PTV, Millington T, Cerqueira-Silva T, Robertson C, de Araújo Oliveira V, Júnior JBS, Alves FJO, Penna GO, Katikireddi SV, Boaventura VS, et al. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study. Lancet Infect Dis. 2022;22(11):1577–86. doi:10.1016/S1473-3099(22)00451-0.
   PubMed Web of Science ®Google Scholar
• Shao W, Chen X, CZheng C, Liu H, Wang G, Zhang B, Li Z, Zhang W. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis. Emerg Microbes Infect. 2022;11(1):2383–92. doi:10.1080/22221751.2022.2122582.
   PubMed Web of Science ®Google Scholar
• Hause AM, Marquez P, Zhang B, Myers TR, Gee J, Su JR, Blanc PG, Thomas A, Thompson D, Shimabukuro TT, et al. Safety monitoring of bivalent COVID-19 mRNA vaccine booster doses among persons aged ≥12 years — United States, August 31–October 23, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(44):1401–6. doi:10.15585/mmwr.mm7144a3.
   PubMed Web of Science ®Google Scholar
• Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, Xie X, Shi P. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. 2023;29(2):344–7. doi:10.1038/s41591-022-02162-x.
   PubMed Web of Science ®Google Scholar
• Behrens GMN, Barros-Martins J, Cossmann A, Ramos GM, Stankov MV, Odak I, Dopfer-Jablonka A, Hetzel L, Köhler M, Patzer G, et al. BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. Nat Commun. 2022;13(1):4872. doi:10.1038/s41467-022-32527-2.
   PubMed Web of Science ®Google Scholar
• Low EV, Tok PSK, Husin M, Suah JL, Tng BH, Thevananthan T, Appannan MR, Yahaya H, Mohd Zin S, Muhamad Zin F, et al. Assessment of heterologous and homologous boosting with inactivated COVID-19 vaccine at 3 months compared with homologous boosting of BNT162b2 at 6 months. JAMA Netw Open. 2022;5(8):e2226046. doi:10.1001/jamanetworkopen.2022.26046.
   PubMed Web of Science ®Google Scholar
• Costa Clemens SA, Milan EP, Sprinz E, Neto JC, Pacciarini F, Li P, Chen HL, Smolenov I, Pollard A, Clemens R. Homologous and heterologous boosting of the Chadox1-S1-S COVID-19 vaccine with the SCB-2019 vaccine candidate: a randomized, controlled, phase 2 study. Open Forum Infect Dis. 2022;9(8):ofac418. doi:10.1093/ofid/ofac418.
   PubMed Web of Science ®Google Scholar
• Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, et al. Homologous and heterologous COVID-19 booster vaccinations. N Engl J Med. 2022;386(11):1046–57. doi:10.1056/NEJMoa2116414.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ma X, Yan G, Wu Y, Chen Y, Zhou Z, Wan N, Su W, Liu F-W, Dai M-X, et al. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: a randomised, double-blinded, placebo-controlled, phase 2 trial. EClinicalMedicine. 2022;54:101680. doi:10.1016/j.eclinm.2022.101680.
   PubMedGoogle Scholar
• Chen C-J, Yang L-Y, Chang W-Y, Huang Y-C, Chiu C-H, Shih S-R, Huang C-G, Huang KYA. A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19. Nat Comm. 2022;13:5466. doi:10.1038/s41467-022-33146-7.
   PubMed Web of Science ®Google Scholar
• Tabarsi P, Anjidani N, Shahpari R, Roshanzamir K, Fallah N, Andre G, Petrovsky N, Barati S. Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: a randomized placebo-controlled trial. Immunology. 2022;167:340–53. doi:10.1111/imm.13540.
   PubMed Web of Science ®Google Scholar
• WHO. Status of COVID-19 vaccines within WHO EUL/PQ evaluation process; [accessed 2023 Sep 6]. https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_12January2023.pdf.
   Google Scholar
• Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, Li P, Liang P, Han HH, Liang J, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10275):682–94. doi:10.1016/S0140-6736(21)00241-5.
   PubMed Web of Science ®Google Scholar
• Bravo L, Smolenov I, Han HH, Li P, Hosain R, Rockhold F, Clemens SAC, Roa C, Borja-Tabora C, Quinsaat A, et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2022;399(10323):461–72. doi:10.1016/S0140-6736(22)00055-1.
   PubMed Web of Science ®Google Scholar
• Roa CC Jr, de Los Reyes MRA, Plennevaux E, Smolenov I, Hu B, Gao F, Ilagan H, Ambrosino D, Siber G, Clemens R. Superior boosting of neutralizing titers against Omicron SARS-CoV-2 variants by heterologous SCB-2019 vaccine vs a homologous booster in CoronaVac-primed adults. J Infect Dis. 2023;22:1253–62. doi:10.1093/infdis/jiad262.
   Google Scholar
• WHO. COVID-19 weekly epidemiological update – edition September 1, 2023; [accessed 2023 Sep 8]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—1-september-2023.
   Google Scholar
• Shirbhate E, Pandey J, Patel VK, Kamal M, Jawaid T, Gorain B, Kesharwani P, Rajak H. Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. Pharmacol Rep. 2021;73(6):1539–50. doi:10.1007/s43440-021-00303-6.
   PubMed Web of Science ®Google Scholar
• Lupala CS, Ye Y, Chen H, Su X-D, Liu H. Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor. Biochem Biophys Res Comm. 2022;590:34–41. doi:10.1016/j.bbrc.2021.12.079.
   PubMed Web of Science ®Google Scholar
• Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657–63. doi:10.1038/s41586-021-04385-3.
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Quach THT, Tran TM, Phuoc HN, Nguyen HT, Vo TK, Vo GV. Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine. Biomed Pharmacother. 2022;147:112650. doi:10.1016/j.biopha.2022.112650.
   PubMed Web of Science ®Google Scholar
• Garg I, Sheikh AB, Pal S, Shekhar R. Mix-and-match COVID-19 vaccinations (heterologous boost): a review. Infect Dis Rep. 2022;14(4):537–46. doi:10.3390/idr14040057.
   PubMed Web of Science ®Google Scholar
• Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N. COVID-19 vaccines mix-and-match: the concept, the efficacy and the doubts. Rev J Med Virol. 2022;94:1294–9. doi:10.1002/jmv.27463.
   PubMed Web of Science ®Google Scholar
• Deng J, Ma Y, Liu Q, Du M, Liu M, Liu J. Comparison of the effectiveness and safety of heterologous booster doses with homologous booster doses for SARS-CoV-2 vaccines: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(17):10752. doi:10.3390/ijerph191710752.
   PubMed Web of Science ®Google Scholar
• Sitaris I, Jacobsen H, Higdon MM, Dowling WE, Bar-Zeev N, Knoll MD. Systemic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant. NPJ Vaccines. 2022;7:147. doi:10.1038/s41541-022-00565-y.
   PubMed Web of Science ®Google Scholar
• Khong K-W, Liu D, Leung K-Y, Lu L, Lam H-Y, Chen L, Chan P-C, Lam H-M, Xie X, Zhang R, et al. Antibody response of combination of BNT162b2 and CoronaVac platforms of COVID-19 vaccines against Omicron variant. Vaccines. 2022;10(2):160. doi:10.3390/vaccines10020160.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao X, Song J, Wu J, Zhu Y, Li M, Cui Y, Chen Y, Yang L, Liu J, et al. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerg Microb Infect. 2022;11:477–81. doi:10.1080/22221751.2022.2030200.
   PubMed Web of Science ®Google Scholar
• Niyomnaitham S, Jongkaewwattana A, Meesing A, Chusri S, Nanthapisal S, Hirankarn N, Siwamogsatham S, Kirdlarp S, Chaiwarith R, Niyom SL, et al. Immune responses of the third dose of AZD1222 vaccine or BNT162b2 mRNA vaccine after two doses of CoronaVac vaccines against Delta and Omicron variants. medRxiv. Preprint posted 2022 Oct 3. doi:10.1101/2022.10.02.22280572.
   Google Scholar
• Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397:2043–6. doi:10.1016/S0140-6736(21)01115-6.
   PubMed Web of Science ®Google Scholar
• Tan CS, Collier AY, Yu J, Liu J, Chandrashekar A, McMahan K, Jacob-Dolan C, He X, Roy V, Hauser BM, et al. Durability of heterologous and homologous COVID-19 vaccine boosts. JAMA Netw Open. 2022;5(8):e2226335. doi:10.1001/jamanetworkopen.2022.26335.
   PubMed Web of Science ®Google Scholar
• Addo IY, Dadzie FA, Okeke SR, Boadi C, Boadu EF. Duration of immunity following full vaccination against SARS-CoV-2: a systematic review. Arch Public Health. 2022;80:200. doi:10.1186/s13690-022-00935-x.
   PubMed Web of Science ®Google Scholar
• Jones JM, Manrique IM, Stone MS, Grebe E, Saa P, Germanio CD, Spencer BR, Notari E, Bravo M, Lanteri MC, et al. Estimates of SARS-CoV-2 seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status — United States, April 2021–September 2022. MMWR Morb Mortal Wkly Rep. 2023;72:601–5. doi:10.15585/mmwr.mm7222a3.
   PubMed Web of Science ®Google Scholar
• WHO. Statement on the antigen composition of COVID-19 vaccines; 2023 May 18 [accessed 2023 Sep 8]. https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines.
   Google Scholar
• EMA. ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants; 2023 June 6 [accessed 2023 Sep 8]. https://www.ema.europa.eu/en/documents/other/ecdc-ema-statement-updating-covid-19-vaccines-composition-new-sars-cov-2-virus-variants_en.pdf.
   Google Scholar
• FDA. 182nd meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC); 2023 June 15 [accessed 2023 Sep 8]. https://www.fda.gov/media/169804/download.
   Google Scholar